The manufacturer of Seroxat® suspension has written to healthcare professionals advised that this product will be discontinued globally with effect from October 2022.
The tablet formulations are unaffected by this announcement and the suspension has been discontinued for commercial reasons. There are no safety concerns.
There are currently no generic suppliers of the suspension. Pharmacies may be able to continue to supply this item through Specials Manufacturers or unlicensed imports. It would be expected that these alternatives would involve a higher cost.
Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to assess if a suitable alternative can be arranged.